A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients

被引:58
作者
Del Toro, G
Satwani, P
Harrison, L
Cheung, YK
Bradley, MB
George, D
Yamashiro, DJ
Garvin, J
Skerrett, D
Bessmertny, O
Wolownik, K
Wischhover, C
van de Ven, C
Cairo, MS
机构
[1] Columbia Univ, Childrens Hosp New York Presbyterian, Dept Pediat, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[2] Columbia Univ, Childrens Hosp New York Presbyterian, Dept Biostat, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[3] Columbia Univ, Childrens Hosp New York Presbyterian, Dept Transfus Med, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
关键词
reduced intensity; allogeneic; pediatric; umbilical cord blood; chimerism;
D O I
10.1038/sj.bmt.1704399
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Reduced intensity (RI) allogeneic stem cell transplantation (AlloSCT) was initially demonstrated in adults following HLA-matched family and unrelated adult donor AlloSCT. There is little information about RI AlloSCT in children. We report results of a pilot study of RI AlloSCT in 21 recipients (less than or equal to21 years). Age: median 13 (0.5-21) years, 8F:13M, 14 unrelated cord blood units (UCB) (10 4/6, 4 5/6), two related BM (6/6, 5/6), four related PBSC (2 6/6, 2 5/6), and one related BM+PBSC (6/6). RI: fludarabine, busulfan (n=14); fludarabine, cyclophosphamide (n=4); fludarabine, melphalan (n=1); total body irradiation, fludarabine, cyclophosphamide (n=1); or fludarabine, cyclophosphamide, and etoposide (n=1). Graft-versus-host disease prophylaxis: FK506 0.03 mg/kg/day and mycophenolate mofetil 15 mg/kg/q 12 h. UCB median nuc/kg and CD34/kg was 4.3x10(7)/kg (0.9-10.8) and 1.9x10(5)/kg (0.3-6.9), and related BM/PBSC median nuc/kg and CD34/kg was 8.3x10(8) (4.7-18.9) and 5.0x10(6)/kg (4.6-6.4). Maximal chimerism following unrelated cord blood transplantation, 100% x7, 98% x1, 95% x2, 55% x1, and 0% x3; related PBSC/BM, 100% x5, 65% x1, and 55% x1. Graft failure occurred in 5/21 (24%). In summary, RI AlloSCT in children is feasible and tolerable (less than or equal to25% GF) and results in greater than or equal to85% of recipients initially achieving greater than or equal to50% donor chimerism.
引用
收藏
页码:613 / 622
页数:10
相关论文
共 54 条
[1]  
ALTER BP, 1991, BLOOD, V78, P602
[2]   Nonmyeloablative stem cell transplantation for congenital immunodeficiencies [J].
Amrolia, P ;
Gaspar, HB ;
Hassan, A ;
Webb, D ;
Jones, A ;
Sturt, N ;
Mieli-Vergani, G ;
Pagliuca, A ;
Mufti, G ;
Hadzic, N ;
Davies, G ;
Veys, P .
BLOOD, 2000, 96 (04) :1239-1246
[3]   Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease [J].
Anderlini, P ;
Giralt, S ;
Andersson, B ;
Ueno, NT ;
Khouri, I ;
Acholonu, S ;
Cohen, A ;
Körbling, MJ ;
Manning, J ;
Romaguera, J ;
Sarris, A ;
Rodriguez, MA ;
Hagemeister, F ;
McLaughlin, P ;
Cabanillas, F ;
Champlin, RE .
BONE MARROW TRANSPLANTATION, 2000, 26 (06) :615-620
[4]   High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].
Badros, A ;
Barlogie, B ;
Morris, C ;
Desikan, R ;
Martin, SR ;
Munshi, N ;
Zangari, M ;
Toor, A ;
Cottler-Fox, M ;
Fassas, A ;
Aniassie, E ;
Schichman, S ;
Tricot, G .
BLOOD, 2001, 97 (09) :2574-2579
[5]   Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning [J].
Barker, JN ;
Weisdorf, DJ ;
DeFor, TE ;
Blazar, BR ;
Miller, JS ;
Wagner, JE .
BLOOD, 2003, 102 (05) :1915-1919
[6]   Malignant neoplasms following bone marrow transplantation [J].
Bhatia, S ;
Ramsay, NKC ;
Steinbuch, M ;
Dusenbery, KE ;
Shapiro, RS ;
Weisdorf, DJ ;
Robison, LL ;
Miller, JS ;
Neglia, JP .
BLOOD, 1996, 87 (09) :3633-3639
[7]   Dose-reduced conditioning for allogeneic blood stem cell transplantation:: durable engraftment without antithymocyte globulin [J].
Bornhäuser, M ;
Thiede, C ;
Schuler, U ;
Platzbecker, U ;
Freiberg-Richter, J ;
Helwig, A ;
Plettig, R ;
Röllig, C ;
Naumann, R ;
Kroschinsky, F ;
Neubauer, A ;
Ehninger, G .
BONE MARROW TRANSPLANTATION, 2000, 26 (02) :119-125
[8]  
Bornhäuser M, 2001, CLIN CANCER RES, V7, P2254
[9]   Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer [J].
Bregni, M ;
Dodero, A ;
Peccatori, J ;
Pescarollo, A ;
Bernardi, M ;
Sassi, I ;
Voena, C ;
Zaniboni, A ;
Bordignon, C ;
Corradini, P .
BLOOD, 2002, 99 (11) :4234-4236
[10]  
Cairo MS, 2001, BLOOD, V98, p354B